Cyprotex Adds In Vitro Toxicology Services

MACCLESFIELD, England, August 20, 2010 - Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today
announces the launch of its new in vitro toxicology service, branded as
Cyprotox(R). Supporting the new service is an additional 90 square metres of
laboratory space at Cyprotex's Macclesfield, UK facility housing the latest
technology in multi-parametric automated fluorescent imaging and cellular
analysis. This gives Cyprotex's Macclesfield site the same in vitro
toxicology capabilities as those of Apredica (Watertown, MA, USA), which
Cyprotex acquired on 6 August 2010.

The new facility includes a Thermo Scientific Cellomics ArrayScan(R) VTI
HCS Reader, which complements the four Cellomics HCS instruments used at
Apredica. The ArrayScan(R) utilises High Content Screening (HCS) technology
to determine multi-parametric indicators of toxicity. HCS is a recent
breakthrough for early toxicology assessment. It has been extensively
validated, and is now being adopted throughout the pharmaceutical industry.

In addition to HCS, the new facility offers many other services to assess
toxicity, including:

    - reactive metabolite detection
    - mitochondrial toxicity;
    - hERG inhibition;
    - toxicological gene regulation;
    - phospholipidosis;
    - phototoxicity;
    - haemolysis;
    - genotoxicity; and
    - a full spectrum of drug-drug interaction assays.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the
launch of the new toxicology facility.

"Drug toxicity, and drug-induced liver injury in particular, is a major
reason for failures in clinical trials and for the withdrawal of previously
approved drugs from the market. Toxicity is the most costly problem in drug
development today. Identifying potential liabilities at an early stage in
drug discovery decreases the likelihood of late-stage failures, and promises
to produce the same magnitude of drug development efficiency improvements
that preclinical ADME has provided.

"Cyprotex's new toxicology facility complements our existing ADME
business, and it aligns the capabilities of our UK facility with those of
Apredica's US facility, which Cyprotex acquired earlier this month. The
combination of in vitro ADME, in vitro toxicology, and Cyprotex's proprietary
predictive modeling and proprietary CellCiphr(TM) technology acquired from
Cellumen gives Cyprotex's customers access to the most extensive and advanced
portfolio of early ADME Tox services on the market today."

    Enquiries:

    Cyprotex PLC
    Tel: +44(0)1625-505-100
    Dr Anthony Baxter, Chief Executive Officer
    John Dootson, Chief Financial Officer
    Mark Warburton, Chief Operating Officer and Legal Counsel
    ir@cyprotex.com
    www.cyprotex.com

    Singer Capital Markets Limited (broker to Cyprotex)
    Tel: +44(0)203-205-7500
    Shaun Dobson
    shaun.dobson@singercm.com
    Claes Spang
    claes.spang@singercm.com
    www.singercm.com

    Financial Dynamics
    Tel: +44(0)20-7831-3113
    Ben Brewerton
    Ben Atwell
    Mo Noonan
    cyprotex@fd.com
    www.fd.com

Enquiries: Cyprotex PLC, Tel: +44(0)1625-505-100, Dr Anthony Baxter, Chief Executive Officer, John Dootson, Chief Financial Officer, Mark Warburton, Chief Operating Officer and Legal Counsel, ir at cyprotex.com; Singer Capital Markets Limited (broker to Cyprotex), Tel: +44(0)203-205-7500, Shaun Dobson, shaun.dobson at singercm.com, Claes Spang, claes.spang at singercm.com; Financial Dynamics, Tel: +44(0)20-7831-3113, Ben Brewerton, Ben Atwell, Mo Noonan, cyprotex at fd.com